EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diclofenac sensitizes multi-drug resistant Acinetobacter baumannii to colistin

Fabiana Bisaro, Clay D Jackson-Litteken, Jenna C McGuffey, Anna J Hooppaw, Sophie Bodrog, Leila Jebeli, Manon Janet-Maitre, Juan C Ortiz-Marquez, Tim van Opijnen, Nichollas E Scott, Gisela Di Venanzio iD, Mario F Feldman iD

PLOS Pathogens · 2024

DOI: 10.1371/journal.ppat.1012705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Fabiana Bisaro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology, Washington University School of Medicine in St. Louis; St. Louis, Missouri, United States of America. Hauptthemen laut MEDLINE: Colistin, Acinetobacter baumannii, Drug Resistance, Multiple, Bacterial, Diclofenac. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, Australian Research Council Future Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acinetobacter baumannii causes life-threatening infections that are becoming difficult to treat due to increasing rates of multi-drug resistance (MDR) among clinical isolates. This has led the World Health Organization and the CDC to categorize MDR A . baumannii as a top priority for the research and development of new antibiotics. Colistin is the last-resort antibiotic to treat carbapenem-resistant A . baumannii . Not surprisingly, reintroduction of colistin has resulted in the emergence of colistin-resistant strains. Diclofenac is a non-steroidal anti-inflammatory drug used to treat pain and inflammation associated with arthritis. In this work, we show that diclofenac sensitizes colistin-resistant A . baumannii clinical strains to colistin in vitro and in a murine model of pneumonia. Diclofenac also reduced the colistin minimal inhibitory concentration (MIC) of Klebsiella pneumoniae and Pseudomonas aeruginosa isolates. Transcriptomic and proteomic analyses revealed an upregulation of oxidative stress-related genes and downregulation of type IV pili induced by the combination treatment. Notably, the concentrations of colistin and diclofenac effective in the murine model were substantially lower than those determined in vitro , implying a stronger synergistic effect in vivo compared to in vitro . A pilA mutant strain, lacking the primary component of the type IV pili, became sensitive to colistin in the absence of diclofenac. This suggest that the downregulation of type IV pili is key for the synergistic activity of these drugs in vivo and indicates that colistin and diclofenac exert an anti-virulence effect. Together, these results suggest that diclofenac can be repurposed with colistin to treat MDR A . baumannii .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColistinAcinetobacter baumanniiDrug Resistance, Multiple, BacterialDiclofenacAcinetobacter InfectionsAnti-Bacterial AgentsMiceAnimalsMicrobial Sensitivity TestsHumansAnti-Inflammatory Agents, Non-SteroidalDrug SynergismDisease Models, Animal

Substanzen

ColistinDiclofenacAnti-Bacterial AgentsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Molecular Microbiology, Washington University School of Medicine in St. Louis; St. Louis, Missouri, United States of America.
  • Biology Department, Boston College; Chestnut Hill, Massachusetts, United States of America.
  • Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne; Melbourne, Australia.
  • Boston Children's Hospital, Division of Infectious Diseases, Harvard Medical School, Boston, Massachusetts, United States of America.

ORCID-Profile: Gisela Di Venanzio, Mario F Feldman

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • Australian Research Council Future Fellowship
  • Discovery Project Grant
  • Australian National Health and Medical Research Council Ideas grant

Zitieren

APA

Bisaro, F., Jackson-Litteken, C. D., McGuffey, J. C., Hooppaw, A. J., Bodrog, S., Jebeli, L., Janet-Maitre, M., Ortiz-Marquez, J. C., van Opijnen, T., Scott, N. E., Di Venanzio, G., & Feldman, M. F. (2024). Diclofenac sensitizes multi-drug resistant Acinetobacter baumannii to colistin. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012705

Vancouver

Bisaro F, Jackson-Litteken CD, McGuffey JC, Hooppaw AJ, Bodrog S, Jebeli L, et al. Diclofenac sensitizes multi-drug resistant Acinetobacter baumannii to colistin. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012705

BibTeX
@article{Bisaro2024,
  author = {Bisaro, Fabiana and Jackson-Litteken, Clay D and McGuffey, Jenna C and Hooppaw, Anna J and Bodrog, Sophie and Jebeli, Leila and Janet-Maitre, Manon and Ortiz-Marquez, Juan C and van Opijnen, Tim and Scott, Nichollas E and Di Venanzio, Gisela and Feldman, Mario F},
  title = {Diclofenac sensitizes multi-drug resistant Acinetobacter baumannii to colistin},
  journal = {PLOS Pathogens},
  year = {2024},
  doi = {10.1371/journal.ppat.1012705}
}
Kostenlos starten →